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Abstract
Background: A key pathogenic role in prion diseases was proposed for a cytosolic form of the prion protein (PrP). However,
it is not clear how cytosolic PrP localization influences neuronal viability, with either cytotoxic or anti-apoptotic effects
reported in different studies. The cellular mechanism by which PrP is delivered to the cytosol of neurons is also debated, and
either retrograde transport from the endoplasmic reticulum or inefficient translocation during biosynthesis has been
proposed. We investigated cytosolic PrP biogenesis and effect on cell viability in primary neuronal cultures from different
mouse brain regions.
Principal Findings: Mild proteasome inhibition induced accumulation of an untranslocated form of cytosolic PrP in cortical
and hippocampal cells, but not in cerebellar granules. A cyclopeptolide that interferes with the correct insertion of the PrP
signal sequence into the translocon increased the amount of untranslocated PrP in cortical and hippocampal cells, and
induced its synthesis in cerebellar neurons. Untranslocated PrP boosted the resistance of cortical and hippocampal neurons
to apoptotic insults but had no effect on cerebellar cells.
Significance: These results indicate cell type-dependent differences in the efficiency of PrP translocation, and argue that
cytosolic PrP targeting might serve a physiological neuroprotective function.
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Introduction
The cellular prion protein (PrP
C) is a glycosylphosphatidylino-
sitol (GPI)-anchored cell-surface glycoprotein with unclear func-
tion that is expressed at the highest level by neurons in the central
nervous system [1,2,3]. Conversion of PrP
C into an abnormal,
misfolded isoform plays a key role in prion diseases, which are
invariably fatal neurodegenerative disorders that can arise
sporadically, be inherited due to mutations in the gene encoding
PrP, or acquired through infection [4].
Research on prion diseases has focused on how perturbations of
PrP
C biosynthesis and metabolism may trigger the neurodegen-
erative process [5]. PrP
C is co-translationally translocated into the
rough endoplasmic reticulum (ER), where the N-terminal signal
peptide (SP) is cleaved, and the GPI anchor is added concurrently
with removal of a C-terminal signal sequence. In the ER, the PrP
polypeptide undergoes oxidative folding with formation of a single
disulphide bond, and the protein is variably modified at two N-
glycosylation sites, resulting in a mixture of di-, mono- and
unglycosylated forms [6]. After transit in the mid-Golgi, where the
immature, core-glycosylated molecules are complex-glycosylated,
PrP is transported through the later compartments of the secretory
pathway and delivered to the cell surface, where it resides in lipid
rafts [7].
The observation that pharmacological inhibition of the protea-
some led to accumulation of an unglycosylated PrP species in
neuroblastoma N2a cells [8,9] was interpreted as evidence that
part of the newly synthesized PrP was constitutively recognized as
misfolded by the ER quality control and diverted to the ER-
associated degradation (ERAD) pathway, which implies retrograde
transport from the ER lumen to the cytosol, deglycosylation by
cytosolic N-glycanases, and proteasomal degradation [10]. Con-
ditions favoring PrP misfolding such as germline or somatic
mutations, and/or reduced proteasome function, might therefore
lead to accumulation of potentially neurotoxic cytosolic PrP.
Consistent with the idea that ERAD-diverted PrP could be
neurotoxic if not properly degraded, forced expression of PrP in
the cytosol caused degeneration of cerebellar granule neurons, and
anatomical and functional abnormalities in the forebrain of
transgenic (Tg) mice [11,12,13].
Cytosolic PrP could also be generated by an ERAD-indepen-
dent mechanism. During PrP biosynthesis a subset of molecules
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[14,15], because of an intrinsic inefficiency of the PrP signal
sequence [16]. The amount of untranslocated PrP increased
during ER stress [17,18], providing an alternative mechanism for
generating potentially neurotoxic cytosolic PrP [19].
However, several observations undermine the idea that cytosolic
PrP is invariably neurotoxic. In non-pathogenic conditions, PrP
was found in the cytoplasm of some neuronal populations in the
hippocampus, neocortex and thalamus, with no signs of
neurodegeneration [20,21,22]. Then too, analysis of cytosolic
PrP activity in different cells produced conflicting results: whereas
some studies confirmed the toxicity [11,16,23,24,25], others did
not [15,26,27], and some brought to light a protective effect
against Bax-mediated cell death [28,29]. These observations raised
the possibility that cells of different neural origin could differ in
their propensity to synthesize PrP in the cytosol, and that this
isoform could have cell type-specific biological activities.
To explore this, we investigated cytosolic PrP biogenesis and
effects on cell survival in primary neuronal cultures from different
mouse brain regions. Here we show that when the proteasome is
inhibited,anunglycosylated formofPrPaccumulatesincorticaland
hippocampal cells, but not in cerebellar granule neurons (CGN).
This form contains uncleaved signal peptides, indicating that it
corresponds to PrP molecules that have escaped translocation into
the ER. Consistent with this, an inhibitor of protein translocation
increased the amount of cytosolic PrP in cortical and hippocampal
neurons, and induced its synthesis in CGNs. Untranslocated PrP
was associated with an increase in the resistance of cortical and
hippocampal cells to apoptosis, but had no such effect on cerebellar
granules. These findings support the conclusion that cytosolic PrP is
not neurotoxic, and suggest that selective targeting of nascent PrP to
the cytosol might fulfill a neuroprotective function.
Results
Untranslocated PrP is Detected in Cultured Cortical and
Hippocampal Neurons, but not in Cerebellar Granules
We investigated whether cytosolic PrP was detectable in
primary neurons cultured from the neocortex, hippocampus and
cerebellum of newborn mice. Because cytosolic PrP is rapidly
degraded by the proteasomes [14,15], cells were treated with a
panel of different proteasome inhibitors. Lactacystin-b-lactone,
MG132 (Z-Leu-Leu-Leu-al), ALLN (Ac-Leu-Leu-NorLeu-al) or
epoxomycin caused accumulation of an insoluble form of PrP of
approximately 27 kDa in cortical and hippocampal neurons
(Fig. 1A, middle and bottom panels, and Fig. 1B top panel). This
form had a larger molecular mass then mature, unglycosylated PrP
in the soluble fractions, and was recognized by an antibody (a-SP),
which selectively reacts with the N-terminal signal peptide of PrP
[30] (Fig. 1B, lower panel), indicating that it corresponded to the
untranslocated form of cytosolic PrP previously described in
transfected cells (hereafter referred to as SP-PrP) [14,15,16,17]. In
cortical and hippocampal cells SP-PrP was first detected after 2 h
treatment, and reached a maximum within 8 h (data not shown)
which, based on quantitative evaluation of Western blots,
corresponded to approximately 10% of total PrP. Consistent with
previous findings [14,15], SP-PrP was not detected in proteasome
inhibitor-treated CGN (Fig. 1A, top panel). PrP levels were similar
in the different neuronal cultures, ruling out that the failure to
detect SP-PrP in CGN was due to lower PrP expression.
During acute ER stress, PrP is prevented from translocating into
the ER and is routed to the cytosol [17,18]. To see whether
proteasome inhibitors activated ER stress pathways in neurons, we
followed the splicing of X-box binding protein 1 (XBP1) mRNA
transcripts [31,32]. Splicing was readily detected in cells treated
with tunicamycin, which inhibits protein glycosylation and induces
ER stress by perturbing the folding efficiency in the ER (Fig. 2A,
lane 5, and 2B, lane 8). No XBP1 splicing was observed in
proteasome inhibitor-treated cells (Fig. 2). There was also no
increase in the ER stress-regulated protein Grp78/Bip in cells
producing untranslocated PrP (data not shown). Thus, accumu-
lation of SP-PrP was due not to an indirect effect of ER stress on
PrP translocation, but to impaired degradation of a cytosolic pool
of native PrP molecules.
Figure 1. Proteasome inhibitors induce accumulation of
insoluble, untranslocated PrP in primary neurons. (A) Cerebellar
granule neurons (CGN), cortical (Cx) and hippocampal (Hipp) neurons
from C57BL/6J mice were treated for 24h with 5 mM epoxomicin
(Epoxo), 100 mM ALLN, 5 mM MG132, or the vehicle alone (CT). Cell
lysates were centrifuged at 186,000 x g for 40 min, and PrP in the
supernatants (S) and pellets (P) was visualized by immunoblotting with
antibody P45-66. The asterisks and arrows indicate bands correspond-
ing to untranslocated PrP and mature, unglycosylated PrP, respectively.
(B) Cortical neurons from Tg(WT-E1) mice were exposed to 5 mM
MG132, epoxomicin (Epoxo), lactacystin b-lactone (b-Lac) or the vehicle
alone (CT). After 24 hours, cells were lysed and centrifuged at 186,000 x
g for 40 min. PrP was visualized by immunoblotting with antibody 3F4
(upper panel), and with an antibody against the N-terminal signal
peptide (a-SP) (lower panel). Molecular mass markers are in kilodaltons.
doi:10.1371/journal.pone.0013725.g001
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hippocampal neurons with a plasmid encoding a PrP-enhanced
green fluorescent protein (PrP-EGFP) fusion molecule [33], and
induced robust synthesis of untranslocated PrP-EGFP by treating
the cells with an inhibitor of PrP translocation (see below). We
imaged PrP-EGFP in fixed, DAPI-stained cells by confocal
microscopy to visualize its localization in relation to the nucleus.
Consistent with previous immunolocalization of a non-fluorescent
version of PrP in cultured neurons [15], PrP-EGFP distributed on
the cell soma and along the neurites of untreated cells (Fig. 3A).
There was also a fraction in intracellular compartments that co-
localized with the ER and Golgi (not shown), as expected for
proteins in transit towards the cell surface. In treated neurons,
PrP-EGFP showed a fine punctate cytoplasmic fluorescence
(Fig. 3B–D), the majority of which did not co-localize with ER
or Golgi markers (Fig. 3C and D, respectively).
Neurons Synthesizing SP-PrP Have Enhanced Resistance
to Proteasome Inhibitor- and Staurosporine-induced Cell
Death
To test the effect of SP-PrP on the viability of cultured neurons
we used a previously described experimental paradigm [11,15].
Neurons cultured from PrP knockout (Prnp
0/0) and wild-type
(Prnp
+/+) mice were exposed to proteasome inhibitors and their
viability was evaluated after 24 h. There was no difference in
viability between Prnp
0/0 and Prnp
+/+ CGN; in contrast, cortical
and hippocampal neurons from Prnp
+/+ mice were significantly
more resistant to the inhibitors than their Prnp
0/0 counterparts
(Fig. 4A–C). Supraphysiological PrP expression further increased
cortical cell resistance to the inhibitors, indicating a dose-
dependent effect of PrP expression on neuronal survival
(Fig. 4D). The fact that the cells that survived best were those
synthesizing SP-PrP suggested that this isoform could have
cytoprotective activity.
To test this, we investigated whether SP-PrP protected neurons
from the toxic effect of staurosporine, a prototypic inducer of
apoptosis [34,35]. Cortical and cerebellar neurons were treated
with or without MG132 for 8 hours (long enough to induce
accumulation of SP-PrP in cortical cells), then incubated for
16 hours with or without staurosporine, before evaluating cell
viability by MTT assay. Statistical analysis showed a significant
protective effect of MG132 against staurosporine-induced cell
death in cortical neurons (Fig. 5A), but no effect on CGN viability
(Fig. 5B). Thus SP-PrP had an anti-apoptotic effect in cortical cells,
consistent with the protective effect of cytosolic PrP against Bax-
induced cell death [28,29].
Inhibition of Protein Translocation Induces Accumulation
of SP-PrP in CGN
Transgenic mice engineered to express PrP in the cytosol show
massive degeneration of CGN, suggesting that cytosolic PrP may
be selectively toxic to these cells [11]. To test this we sought ways
to induce cytosolic PrP localization in cultured CGN. CAM741, a
cyclopeptolide that inhibits co-translational translocation by
interfering with the correct insertion of the signal peptide into
the translocon [36,37], increased the amount of SP-PrP in
hippocampal and cortical neurons (Fig. 6A, compare lanes 4
and 6, and data not shown). CAM741 induced an unglycosylated
PrP species in CGN (Fig. 6B, lanes 7 and 8), which was confirmed
identical to SP-PrP by reactivity with the a-SP antibody and an
antibody directed against the C-terminal GPI-anchoring signal (a-
GP) [17] (Fig. 6B, right). When we analyzed how SP-PrP
accumulation affected CGN viability, we found no significant
difference between cells treated with MG132 alone or in
combination with CAM741 (Fig. 6C), even though the latter
accumulated SP-PrP (Fig. 6B, lanes 7 and 8).
Next, we tested the effect of SP-PrP in CGN deprived of serum
and potassium, a condition that induces apoptotic cell death [38].
After 24 h of deprivation, CGN viability was reduced by ,30%
(Fig. 7B). CAM741 alone, or combined with MG132 to induce
accumulation of SP-PrP (Fig. 7A, lanes 7 and 8), caused a small
but significant decrease of cell survival (Fig. 7B, gray bars).
Figure 2. Proteasome inhibitors do not induce ER stress in primary neurons. Cortical (A) or cerebellar granule neurons (B) were treated with
5 mM MG132 or epoxomicin (Epoxo) for the times indicated, with 5 mM MG132 and 10 mM CAM741 for 18 h, or 5 mg/ml tunicamycin (Tm) for 8 h.
After treatment, total RNA was extracted and analyzed by reverse transcription-PCR. XBP1 splicing was determined by the appearance of rapidly
migrating spliced XBP1 in tunicamycin-treated cells. The arrows point to unspliced (uXBP1) and spliced (sXBP1) transcripts.
doi:10.1371/journal.pone.0013725.g002
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0/0 mice (Fig. 7B,
white bars), indicating that the loss of cell viability was due to a
toxic effect of the treatment, independent of SP-PrP.
Finally, we used an experimental paradigm similar to that
shown in Fig. 5 to test whether CAM741-induced SP-PrP
protected CGN from staurosporine toxicity. SP-PrP had no effect
on cell viability (not shown). Thus, in CGN, SP-PrP was not toxic,
and did not protect from apoptosis.
Discussion
The cellular pathways by which cytosolic PrP is generated and
the biological activity of this species have been debated. Previous
investigations have used transfected cells or transgenic mice
engineered to express artificial PrP molecules in the cytosol,
making extrapolation to physiological conditions difficult. In the
present study we investigated the biogenesis and biological activity
of cytosolic PrP produced endogenously in primary neurons from
different mouse brain regions. The efficiency of PrP compartmen-
talization in the secretory pathway varied significantly for different
neurons, with cortical and hippocampal cells synthesizing an
untranslocated form of cytosolic PrP, which was not present in
cerebellar granules. Synthesis of untranslocated PrP caused no
toxicity to neurons –in fact, it increased resistance to apoptosis.
These data indicate that inefficient co-translational translocation
during biogenesis is the primary source of cytosolic PrP in neurons,
and raise the possibility that cytosolic targeting of nascent PrP
molecules might be physiologically regulated for cellular benefit.
Proteasome inhibitors induced accumulation of an unglycosy-
lated form of PrP in primary neurons. This form had a higher
molecular mass than mature, unglycosylated PrP and carried the
N- and C-terminal signals that are cleaved in the ER lumen. Thus,
cytosolic PrP represents untranslocated molecules that have never
entered the ER rather than retrogradely translocated PrP, which
would lack both signal peptides. In cultured neurons untranslo-
cated PrP showed a fine punctate cytosolic localization reminiscent
of that in certain brain neurons [20,21,22].
ER stress favors accumulation of untranslocated PrP by
activating a ‘‘preemptive’’ quality control mechanism that inhibits
protein translocation [17,18]. Therefore it was important to verify
whether proteasome inhibitors activated ER stress pathways in
neuronal cells [39]. There was no evidence of splicing of the mRNA
encoding XBP-1 or increases in the levels of the ER stress-regulated
protein Grp78/BiP. This indicated that SP-PrP accumulation in
response to proteasome inhibition was due not to an indirect effect
ofERstress,buttoa poolofshort-lived PrPmoleculesinthe cytosol.
Unlike cortical and hippocampal cells, we detected no SP-PrP in
cerebellar granules unless translocation was pharmacologically
inhibited. This is in line with analyses of the mouse brain, where
cytosolic PrP was detected in neurons of the neocortex and
hippocampus, but not the cerebellum [20,21], and suggests that
cell-specific factors influence PrP translocation. Consistent with
this conclusion, the efficiency of PrP compartmentalization in the
secretory pathway varied markedly in different cell lines [40].
The molecular steps leading to signal-mediated protein segregation
into the mammalian ER include recognition of the nascent
polypeptide chain by the signal recognition particle (SRP), followed
by SRP-dependent targeting to the ER membrane and transfer to the
Sec61 translocon. The nascent polypeptide is then inserted into the
protein-conducting channel of the translocon, allowing protein
Figure 3. Untranslocated PrP shows cytosolic localization. Hippocampal neurons from C57BL/6J mice were transfected with a plasmid
encoding PrP-EGFP (green). Twelve days after transfection cells were exposed to the vehicle (A) or treated with 10 mM CAM741 for 24 h plus 5 mM
MG132 during the last 6 h (B–D). Cells were then fixed and reacted with DAPI (blue) to stain the nuclei. Cells in C and D were also immunostained
with an anti-PDI or anti-golgin antibody (red) to visualize the ER and Golgi, respectively. Scale bar =10 mm in A (also applicable to B), and 5 mmi nC
(also applicable to D).
doi:10.1371/journal.pone.0013725.g003
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amount of SP-PrP increased in response to CAM741, which
interferes with the correct insertion of the signal peptide into the
translocon [36,37], suggests that a post-targeting interaction between
the signal and the Sec61 channel is primarily involved in PrP
translocation, a conclusion also emerging from other studies [18,42].
Several ‘‘accessory’’ components influence post-targeting PrP
translocation, such as the translocon-associated protein complex
TRAP [43], and chaperones and disulfide isomerases that
associate with the cytoplasmic side of Sec61 [44]. It remains to
be established whether regulated expression of these proteins
governs SP-PrP synthesis in neuronal cells.
Consistent with evidence of an anti-apoptotic function of
cytosolic PrP [28], SP-PrP protected neurons against the toxicity
of proteasome inhibitors and staurosporine, which activate the
intrinsic apoptotic pathway [35,45]. This effect was seen in cortical
and hippocampal cells, but not in cerebellar granules where
CAM741 induced SP-PrP. This suggests there are specific factors
that influence the activity of SP-PrP, for example PrP-interacting
proteins that may be selectively expressed or functionally more
critical in some cell types than others. A number of proteins have
been identified that could interact with PrP in the cytosol and
mediate neuroprotection, including the anti-apoptotic protein Bcl-
2 [46] and the neurotrophin receptor-interacting MAGE homo-
logue, NRAGE [47]. However, preliminary attempts to identify a
physical interaction between SP-PrP and these candidate proteins
have not been rewarding (unpublished data). The fact that
untranslocated PrP has a short half-life [14] suggests it may engage
only in transient interactions.
The neuroprotective activity of untranslocated PrP produced
endogenously in cultured neurons contrasts with the neurotoxicity
of forced cytosolic PrP expression by transgenesis. A PrP construct
lacking N- and C-terminal signal peptides, designed to mimic
cytosolic PrP from retrotranslocation, caused massive degenera-
tion of CGN in transgenic mice [11]. Although this observation is
provocative, the lack of evidence of cytosolic PrP generation by
retrotranslocation in neuronal cells [14,15, and this study] raises
questions about its pathologic importance.
Rane and colleagues generated Tg mice expressing a variant of
hamster PrP carrying the interferon-c signal peptide (Ifn-PrP),
which was constitutively translocated at low levels [19]. Trans-
genic mice expressing small amounts of Ifn-PrP (1/6th of the
endogenous PrP mRNA level) were smaller than non-Tg
littermates and developed mild ataxia with modest spongiform
changes at 18–24 months of age. Tg lines with higher Inf-PrP
expression could not be established because of embryonic and
neonatal lethality [19]. This indicates that constitutive expression
of untranslocated PrP during development is highly detrimental,
perhaps underscoring the importance of regulated PrP transloca-
tion early in the mouse’s life.
The signal sequence of PrP has evolved to maintain a slight but
measurable inefficiency in interaction with the translocon [42,48].
This allows generation of multiple topological forms of the protein,
including untranslocated PrP and
CtmPrP, a transmembrane
variant with neurotoxic properties [49,50,51]. It is therefore
tempting to speculate that PrP might have acquired the ability to
adopt cytosolic or transmembrane topologies with opposite effects
on neuronal survival for a functional purpose, perhaps to fine-tune
Figure 4. Neurons synthesizing SP-PrP are more resistant to proteasome inhibitors. Cerebellar granule neurons (CGN), cortical (Cx) and
hippocampal (Hipp) neurons prepared from C57BL/6J (Prnp
+/+) and PrP knockout (Prnp
0/0) mice were exposed to 1 mM epoxomicin (A), 100 mM ALLN
(B) or 5 mM MG132 (C). Cell survival was quantified after 24 h by MTT assay and expressed as a percentage of the values for cells treated with the
vehicle. Data are the mean 6 SEM of 12–24 replicates from 2–4 independent experiments; **p,0.01 by Tukey-Kramer test. (D) Cortical neurons were
prepared from Prnp
0/0 (PrP level: 0X), Prnp
+/+ (PrP level: 1X), and Tg(WT-E1)
+/2/Prnp
+/0 (PrP level: ,2.5X) littermates obtained by crossing
Tg(WT-E1)
+/2/Prnp
+/0 and Prnp
+/0 mice. Cell viability was analyzed after 24-h treatment with 5 mM MG132 and expressed as a percentage of the
values for cells treated with the vehicle. Data are the mean 6 SEM of 8-23 replicates from 2 independent experiments; *p,0.05, ***p,0.001 by
Dunnett’s test.
doi:10.1371/journal.pone.0013725.g004
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[2,52]. In certain species cytosolic PrP can be generated by
alternative initiation of translation, which produces PrP molecules
with short signal peptides unable to negotiate entry into the ER
[53,54]. Thus different molecular strategies might have evolved to
produce untranslocated PrP.
A number of secretory and membrane proteins appear to have
inefficient signal sequences for beneficial functions. Thus, during
ER stress, proteins such as PrP are prevented from entering the
secretory pathway to alleviate the burden of the folding and
secretory transport machineries of the cell [17,18]. We have
provided evidence that a pool of untranslocated cytosolic PrP is
synthesized in certain neurons in the absence of ER stress,
indicating the existence of cell type-specific pathways that control
PrP translocation in physiological conditions. We also report a
beneficial effect of untranslocated PrP on neuronal survival,
suggesting a new teleological argument for the evolutionary
conserved inefficiency of the PrP signal sequence. The challenge
for future studies will be to elucidate the cellular mechanisms
regulating the biogenesis of untranslocated PrP, and the
downstream molecular pathways that mediate its biological effect.
Materials and Methods
Mice
Production of Tg(WT-E1) mice overexpressing mouse wild-type
PrP (moPrP) tagged with an epitope for the monoclonal antibody
3F4 has been reported elsewhere [55]. Prnp
0/0 mice [56] with a
pure C57BL/6J background were obtained from the European
Mouse Mutant Archive (Monterotondo, Rome, Italy). C57BL/6J
mice were purchased from Charles River Laboratories.
Figure 5. MG132 protects cortical but not cerebellar granule
neurons from staurosporine-induced cell death. Cortical (A, Cx)
and cerebellar granule neurons (B, CGN) from C57BL/6J mice were
exposed to 5 mM MG132 for 8 h to induce accumulation of SP-PrP in
cortical neurons, and treated with 100 nM staurosporine or not for 16 h.
Cell survival was quantified at the end of the treatment (24 h) by MTT
assay and expressed as a percentage of the values for cells treated with
the vehicle. Data are the mean 6 SEM of 20–25 replicates from four
independent experiments; **p,0.01 by Bonferroni test.
doi:10.1371/journal.pone.0013725.g005
Figure 6. SP-PrP has no effect on viability of cerebellar granule
neurons. (A) Hippocampal neurons from C57BL/6J mice were treated
with 5 mM MG132 alone or with 10 mM CAM741 for 18 h, and PrP was
analyzed by Western blot as described in the legend to Fig. 1. Note the
higher level of SP-PrP in the presence of CAM741 (compare lanes 4 and
6). (B) Cerebellar granule neurons from C57BL/6J mice were treated
with 10 mM CAM741, 10 mM MG132 or with the two drugs simulta-
neously for 24 h, before Western blot analysis with antibody 12B2. The
PrP band in lane 8 also reacted with the a-SP and a-GP antibodies (on
the right). (C) Cell survival was quantified by MTT assay and expressed
as a percentage of the values for cells treated with the vehicle. Data are
the mean 6 SEM of 18–20 replicates from two independent
experiments. The Bonferroni test did not find any difference between
MG132 and CAM+MG groups.
doi:10.1371/journal.pone.0013725.g006
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All procedures involving animals were conducted according to
European Union (EEC Council Directive 86/609, OJ L 358,1;
December 12, 1987) and Italian (D.L. n.116, G.U. suppl. 40,
February 18, 1992) laws and policies, and were in accordance with
the United States Department of Agriculture Animal Welfare Act
and the National Institutes of Health Policy on Humane Care and
Use of Laboratory Animals. They were reviewed and approved by
the Mario Negri Institute Animal Care and Use Committee that
includes ad hoc members for ethical issues (ID 9/1/01). Animal
facilities meet international standards and are regularly checked by a
certified veterinarianwhoisresponsibleforhealthmonitoring, animal
welfaresupervision, experimentalprotocolsandreview ofprocedures.
Cell Culture
Primary neuronal cultures were prepared as previously
described [15,57]. Briefly, cerebella were dissected, sliced into
,1-mm pieces and incubated in Hank’s balanced salt solution
(HBSS, Gibco) containing 0.3 mg/ml trypsin (Sigma) at 37uC for
15 min. Trypsin inhibitor (Sigma) was added to a final
concentration of 0.5 mg/ml and the tissue was mechanically
dissociated by passing through a flame-polished Pasteur pipette.
Cells were plated at 350–400,000 cells/cm
2 on poly-L-lysine
(0.1 mg/ml)-coated plates. Cells were maintained in Basal
Medium Eagle (Gibco) supplemented with 10% dialyzed fetal
bovine serum (FBS, Sigma), penicillin/streptomycin and KCl
25 mM, at 37uC in an atmosphere of 5% CO2, 95% air.
Cortical and hippocampal neurons were prepared from two-
day-old animals as described [57]. Brain tissue was sliced into
,1-mm pieces and incubated in HBSS (Gibco) containing
20 U/ml papain (Sigma) at 34uC for 30 min. Trypsin inhibitor
(Sigma) was added to a final concentration of 0.5 mg/ml and the
tissue was mechanically dissociated by passing through a
flame-polished Pasteur pipette. Cells were plated at 150–250,000
cells/cm
2 on poly-D-lysine-coated (25 mg/ml) plates and main-
tained in Neurobasal Basal Medium (Gibco) supplemented with
B27 (Gibco), penicillin/streptomycin and glutamine 2 mM. To
reduce the number of non-neuronal cells, aphidicolin (3.3 mg/ml,
Sigma) was added to the medium 48 h after plating. Non-neuronal
contamination was less than 3%.
Cell viability was assessed by measuring the cellular reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) to formazan [57]. Cells were incubated for 3 h at 37uC
with 0.4 mg/ml MTT, dissolved in 0.04N HCl in 2-propanol, and
analyzed spectrophotometrically at 540 nm with an automatic
microplate reader (Labsystems Multiskan MS).
Cell Transfection
Hippocampal neurons were transfected with a plasmid
encoding a moPrP molecule containing a monomerized version
of enhanced green fluorescent protein (EGFP) inserted after codon
34 [33], using the Nucleofector device and the Mouse Neuron
Nucleofector Kit (Lonza). Cells were then pelleted, resuspended in
RPMI 1640 (Gibco) containing 10% FBS (Sigma) and 2 mM
glutamine, and plated at 300,000 cells/cm
2 on poly-D-lysine
(25 mg/ml)-coated plates. After 2 h the medium was replaced with
Neurobasal Basal Medium (Gibco) supplemented with B27
(Gibco), penicillin/streptomycin and glutamine 2 mM, and cells
were maintained at 37uC in an atmosphere of 5% CO2, 95% air.
They were analyzed after 12–14 days in culture.
Antibodies
Monoclonal antibody 3F4 was diluted 1:5,000 [58]. Rabbit
polyclonal antibody P45-66, raised against a synthetic peptide
encompassing residues 45–66 of moPrP, was used at 1:2,500 [59].
An affinity-purified polyclonal rabbit antibody (a-SP) that
selectively recognizes forms of moPrP containing an uncleaved
signal peptide was used at 1:150 [30]. A rabbit polyclonal antibody
(a-GP) raised against the C-terminal sequence of moPrP, which is
removed before the addition of the GPI anchor was used at
1:1,000 [17]. Monoclonal antibody 12B2 against moPrP sequence
88–92 was used at 1:5,000 [60]. Polyclonal rabbit antibodies
against protein disulfide isomerase (PDI, Sigma) and giantin
(Covance) were used at 1:500.
Biochemical Analysis
To assay detergent insolubility, cells were lysed in 10 mM Tris
pH 7.5, 100 mM NaCl, 0.5% sodium deoxycholate and 0.5%
Nonidet P-40 containing protease inhibitors (pepstatin and
leupeptin, 1 mg/ml; phenylmethylsulfonyl fluoride, 0.5 mM; and
ethylenediaminetetraacetic acid, 2 mM). Lysates corresponding to
300 mg of protein were centrifuged at 186,000 x g for 40 min in a
Beckman Optima Max-E ultracentrifuge. Proteins in the pellet
Figure 7. SP-PrP does not affect the cerebellar granule
neurons’ response to serum and potassium deprivation. (A)
Cerebellar granule neurons from C57BL/6J mice were shifted to serum-
free medium containing 5 mM KCl, and left untreated (-) or treated with
10 mM CAM741 alone or in combination with 10 mM MG132 to induce
accumulation of SP-PrP. After 24 h cells were analyzed by Western blot
with antibody 12B2 to verify the induction of SP-PrP. (B), Cell survival
was quantified by MTT assay and expressed as a percentage of the
values for untreated cells. Data are the mean 6 SEM of 12 replicates;
**p,0.01, ***p,0.001 vs -K
+ in Prnp
+/+;
##p,0.01 vs -K
+ in Prnp
0/0 by
Bonferroni test.
doi:10.1371/journal.pone.0013725.g007
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polyacrylamide gel electrophoresis and electro-transferred onto
polyvinylidene fluoride membranes (Immobilon P, Millipore).
Membranes were incubated first with 5% non-fat dry milk in
100 mM Tris pH 7.5, 150 mM NaCl and 0.1% Tween 20
(TTBS), then with anti-PrP antibodies overnight at 4uCo r1ha t
room temperature, rinsed three times with TTBS and incubated
1 h at room temperature with horseradish peroxidase-conjugated
secondary antibody (diluted 1:5,000; Santa Cruz). Signals were
revealed using enhanced chemiluminescence (Amersham Biosci-
ences), and visualized by a Biorad XRS image scanner.
Quantitative densitometry of protein bands was done using
Quantity One software (Biorad).
XBP1 Splicing
Total RNA was extracted using a commercial kit (SV Total
RNA Isolation System; Promega, Madison, WI), according to the
manufacturer’s instructions. RNA samples were reverse-tran-
scribed with MuLV Reverse Transcriptase (Applied Biosystems)
by priming with oligo(dT). XBP1 mRNA was amplified with
primers flanking the 26b intron (59-GGAGTGGAGTAAG-
GCTGGTG and 59-CCAGAATGCCCAAAAGGATA) and
PCR products resolved on 2.5% agarose gels [17].
Immunofluorescence Staining
Cells grown on 8-well 15-mm slides (Ibidi, Martinsried,
Germany) were washed with phosphate buffered saline (PBS)
and fixed for 30 min at room temperature with 4% paraformal-
dehyde in PBS. They were then washed with PBS, incubated with
blocking solution containing 0.1% saponin, 0.5% BSA, 50 mM
NH4Cl in PBS, and with primary and Alexa (Molecular Probes)-
conjugated secondary antibodies diluted in the same solution.
Cells were stained with 1 mg/ml DAPI (Sigma Aldrich) for 5 min
and analyzed with an Olympus FV500 laser confocal scanning
system.
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